OCUL vs. INVA, PLRX, ARQT, PHAT, KNSA, AXSM, MRUS, RARE, INSM, and HCM
Should you be buying Ocular Therapeutix stock or one of its competitors? The main competitors of Ocular Therapeutix include Innoviva (INVA), Pliant Therapeutics (PLRX), Arcutis Biotherapeutics (ARQT), Phathom Pharmaceuticals (PHAT), Kiniksa Pharmaceuticals (KNSA), Axsome Therapeutics (AXSM), Merus (MRUS), Ultragenyx Pharmaceutical (RARE), Insmed (INSM), and HUTCHMED (HCM). These companies are all part of the "pharmaceutical preparations" industry.
Ocular Therapeutix (NASDAQ:OCUL) and Innoviva (NASDAQ:INVA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations, community ranking, media sentiment and valuation.
Innoviva has higher revenue and earnings than Ocular Therapeutix. Ocular Therapeutix is trading at a lower price-to-earnings ratio than Innoviva, indicating that it is currently the more affordable of the two stocks.
Ocular Therapeutix received 131 more outperform votes than Innoviva when rated by MarketBeat users. Likewise, 69.72% of users gave Ocular Therapeutix an outperform vote while only 57.28% of users gave Innoviva an outperform vote.
In the previous week, Ocular Therapeutix had 2 more articles in the media than Innoviva. MarketBeat recorded 7 mentions for Ocular Therapeutix and 5 mentions for Innoviva. Innoviva's average media sentiment score of 1.75 beat Ocular Therapeutix's score of 1.42 indicating that Innoviva is being referred to more favorably in the news media.
Innoviva has a net margin of 58.21% compared to Ocular Therapeutix's net margin of -192.61%. Innoviva's return on equity of 28.94% beat Ocular Therapeutix's return on equity.
Ocular Therapeutix presently has a consensus price target of $15.17, indicating a potential upside of 158.38%. Given Ocular Therapeutix's higher probable upside, research analysts plainly believe Ocular Therapeutix is more favorable than Innoviva.
59.2% of Ocular Therapeutix shares are held by institutional investors. Comparatively, 99.1% of Innoviva shares are held by institutional investors. 5.5% of Ocular Therapeutix shares are held by company insiders. Comparatively, 1.4% of Innoviva shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.
Ocular Therapeutix has a beta of 1.47, meaning that its share price is 47% more volatile than the S&P 500. Comparatively, Innoviva has a beta of 0.57, meaning that its share price is 43% less volatile than the S&P 500.
Summary
Innoviva beats Ocular Therapeutix on 9 of the 17 factors compared between the two stocks.
Get Ocular Therapeutix News Delivered to You Automatically
Sign up to receive the latest news and ratings for OCUL and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding OCUL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Ocular Therapeutix Competitors List
Related Companies and Tools
